

# ZOGENIX

## Zogenix to Participate in LEERINK Partners 5th Annual Global Healthcare Conference

February 3, 2016

EMERYVILLE, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Bradley S. Galer, M.D., Executive Vice President and CMO, will present a corporate update at the LEERINK Partners 5<sup>th</sup> Annual Global Healthcare Conference in New York, NY, on February 10, 2016.

### **LEERINK Partners 5<sup>th</sup> Annual Global Healthcare Conference -- Zogenix Presentation Details**

Date: Wednesday, February 10, 2016  
Time: 10:40 am Eastern Time / 7:40 am Pacific Time  
Location: New York, NY - The Waldorf Astoria Hotel, Metropolitan Suite

The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at [ir.zogenix.com](http://ir.zogenix.com).

### **About Zogenix**

Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.

For more information, visit [www.zogenix.com](http://www.zogenix.com).

### CONTACT:

Investors: Andrew McDonald  
Founding Partner, LifeSci Advisors LLC  
646-597-6987 | [Andrew@lifesciadvisors.com](mailto:Andrew@lifesciadvisors.com)

Zogenix, Inc.